162 related articles for article (PubMed ID: 22516398)
1. Provoked exercise desaturation in patent foramen ovale and impact of percutaneous closure.
Devendra GP; Rane AA; Krasuski RA
JACC Cardiovasc Interv; 2012 Apr; 5(4):416-9. PubMed ID: 22516398
[TBL] [Abstract][Full Text] [Related]
2. Primary transcatheter patent foramen ovale closure is effective in improving migraine in patients with high-risk anatomic and functional characteristics for paradoxical embolism.
Rigatelli G; Dell'Avvocata F; Ronco F; Cardaioli P; Giordan M; Braggion G; Aggio S; Chinaglia M; Rigatelli G; Chen JP
JACC Cardiovasc Interv; 2010 Mar; 3(3):282-7. PubMed ID: 20298985
[TBL] [Abstract][Full Text] [Related]
3. Electrocardiographic changes and arrhythmias following percutaneous atrial septal defect and patent foramen ovale device closure.
Johnson JN; Marquardt ML; Ackerman MJ; Asirvatham SJ; Reeder GS; Cabalka AK; Cetta F; Hagler DJ
Catheter Cardiovasc Interv; 2011 Aug; 78(2):254-61. PubMed ID: 21563292
[TBL] [Abstract][Full Text] [Related]
4. Figulla PFO occluder versus Amplatzer PFO occluder for percutaneous closure of patent foramen ovale.
Saguner AM; Wahl A; Praz F; de Marchi SF; Mattle HP; Cook S; Windecker S; Meier B
Catheter Cardiovasc Interv; 2011 Apr; 77(5):709-14. PubMed ID: 20931665
[TBL] [Abstract][Full Text] [Related]
5. Percutaneous Intervention to Treat Platypnea-Orthodeoxia Syndrome: The Toronto Experience.
Shah AH; Osten M; Leventhal A; Bach Y; Yoo D; Mansour D; Benson L; Wilson WM; Horlick E
JACC Cardiovasc Interv; 2016 Sep; 9(18):1928-38. PubMed ID: 27659570
[TBL] [Abstract][Full Text] [Related]
6. Clinical Performance of the New Gore Septal Occluder in Patent Foramen Ovale Closure: A Single-Center Experience.
Sganzerla P; Rondi M; Pavone A; Aiolfi E; Facchinetti A; Funaro A; Negrini P
J Invasive Cardiol; 2015 Sep; 27(9):430-4. PubMed ID: 26332878
[TBL] [Abstract][Full Text] [Related]
7. Platypnea-orthodeoxia syndrome in the elderly treated by percutaneous patent foramen ovale closure: a case series and literature review.
Blanche C; Noble S; Roffi M; Testuz A; Müller H; Meyer P; Bonvini JM; Bonvini RF
Eur J Intern Med; 2013 Dec; 24(8):813-7. PubMed ID: 24007641
[TBL] [Abstract][Full Text] [Related]
8. Percutaneous closure of a patent foramen ovale causing exercise hypoxemia: Case report and a review of the literature.
Punzengruber G; Kolb R; Meier B; Binder RK
Catheter Cardiovasc Interv; 2021 Oct; 98(4):733-737. PubMed ID: 34145952
[TBL] [Abstract][Full Text] [Related]
9. The effect of patent foramen ovale closure in patients with platypnea-orthodeoxia syndrome.
Mojadidi MK; Gevorgyan R; Noureddin N; Tobis JM
Catheter Cardiovasc Interv; 2015 Oct; 86(4):701-7. PubMed ID: 26063336
[TBL] [Abstract][Full Text] [Related]
10. Patent foramen ovale closure with the Intrasept occluder: Complete 6-56 months follow-up of 247 patients after presumed paradoxical embolism.
Spies C; Timmermanns I; Reissmann U; van Essen J; Schräder R
Catheter Cardiovasc Interv; 2008 Feb; 71(3):390-5. PubMed ID: 18288745
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous transcatheter closure of patent foramen ovale with the Amplatzer Cribriform septal occluder.
Silvestry FE; Naseer N; Wiegers SE; Hirshfeld JW; Herrmann HC
Catheter Cardiovasc Interv; 2008 Feb; 71(3):383-7. PubMed ID: 18288733
[TBL] [Abstract][Full Text] [Related]
12. Safety and performance of the Spider™ patent foramen ovale occluder.
Edwards-Lehr T; Franke J; Bertog SC; Bäcker C; Wunderlich N; Hofmann I; Wilson N; Piechaud JF; Sievert H
Catheter Cardiovasc Interv; 2013 Feb; 81(2):317-23. PubMed ID: 22887130
[TBL] [Abstract][Full Text] [Related]
13. Explantation of patent foramen ovale closure devices: a multicenter survey.
Verma SK; Tobis JM
JACC Cardiovasc Interv; 2011 May; 4(5):579-85. PubMed ID: 21596333
[TBL] [Abstract][Full Text] [Related]
14. Positional oxygen desaturation: the spectrum of postural changes in arterial oxygen is wider than the pure platypnea-orthodeoxia syndrome.
Colombo A; Danna P; Cialfi A; Belloni A; Viecca M
J Cardiovasc Med (Hagerstown); 2014 May; 15(5):431-3. PubMed ID: 23549278
[No Abstract] [Full Text] [Related]
15. Short and long term complications of device closure of atrial septal defect and patent foramen ovale: meta-analysis of 28,142 patients from 203 studies.
Abaci A; Unlu S; Alsancak Y; Kaya U; Sezenoz B
Catheter Cardiovasc Interv; 2013 Dec; 82(7):1123-38. PubMed ID: 23412921
[TBL] [Abstract][Full Text] [Related]
16. Residual shunting after percutaneous PFO closure: how to manage and how to close.
Butera G; Sarabia JF; Saracino A; Chessa M; Piazza L; Carminati M
Catheter Cardiovasc Interv; 2013 Nov; 82(6):950-8. PubMed ID: 23804551
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous closure of patent foramen ovale with a bioabsorbable occluder device: single-centre experience.
Ussia GP; Cammalleri V; Mulè M; Scarabelli M; Barbanti M; Scardaci F; Mangiafico S; Immè S; Capodanno D; Tamburino C
Catheter Cardiovasc Interv; 2009 Oct; 74(4):607-14. PubMed ID: 19360875
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of patent foramen ovale and usefulness of percutaneous closure device in carcinoid heart disease.
Mansencal N; Mitry E; Pillière R; Lepère C; Gérardin B; Petit J; Gandjbakhch I; Rougier P; Dubourg O
Am J Cardiol; 2008 Apr; 101(7):1035-8. PubMed ID: 18359327
[TBL] [Abstract][Full Text] [Related]
19. New onset atrial fibrillation after patent foramen ovale closure.
Staubach S; Steinberg DH; Zimmermann W; Wawra N; Wilson N; Wunderlich N; Sievert H
Catheter Cardiovasc Interv; 2009 Nov; 74(6):889-95. PubMed ID: 19626689
[TBL] [Abstract][Full Text] [Related]
20. Initial clinical experience with the Coherex FlatStent™ and FlatStent™ EF PFO closure system for in-tunnel PFO closure: results of the Coherex-EU study.
Sievert H; Wunderlich N; Reiffenstein I; Ruygrok P; Grube E; Buellesfeld L; Meier B; Schofer J; Muller D; Jones RK; Gillam L
Catheter Cardiovasc Interv; 2014 Jun; 83(7):1135-43. PubMed ID: 22815250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
